Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
3.30    0.00 (0.00%)
Bid:
3.20
Ask:
3.40
Spread: 0.20 (6.25%)
Market Cap: £26.51m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

Thymolflex EPA approval

2 Apr 2026 07:00

RNS Number : 1487Z
Eden Research plc
02 April 2026
 

As the information in this release pertains to EDEN RESEARCH PLC, this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR"), which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

2 April 2026

 

 

Eden Research Plc

("Eden" or "Company")

 

Thymolflex® EPA approval

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, is pleased to announce that the Company's partner, Véto-pharma, has received regulatory approval from the US Environmental Protection Agency ("EPA") for Thymolflex® for use in integrated Varroa management. Thymoflex® is a thymol-based treatment used in bee health to control Varroa destructor, an external parasitic mite that attacks and feeds on honey bees. This approval follows an announced agreement, signed by the Company in April 2025, to supply Véto-pharma with thymol for use in bee care products.

 

Supporting integrated Varroa management strategies

 

Varroa destructor remains one of the most significant threats to honey bee health worldwide. As resistance concerns increase and environmental conditions become more unpredictable, beekeepers need multiple authorised tools that can be adapted to different colony conditions and management systems.

 

Thymoflex® is based on thymol, a well-known active substance of natural origin, widely used by beekeepers as part of integrated pest management (IPM) programs.

 

Thymoflex® is a ready-to-use thymol gel designed for straightforward handling and application in the apiary. The product allows for a controlled release of thymol within the hive, contributing to effective mite control when used according to label directions. Its formulation aims to combine ease of use, consistency, and colony safety, making it suitable for professional beekeeping operations.

 

By expanding access to thymol-based solutions, Thymoflex® offers beekeepers an additional option to:

· A treatment based on a naturally derived active substance

· Flexible use within the beekeeping season, according to label instructions

· Reduce reliance on a single mode of action

· Proven efficacy against varroa, including in the presence of brood

· Compatibility with treatment rotation programs, helping to manage resistance risks

· Enhance grooming behaviour and overall hygienic responses in honey bee colonies.

 

The gel formulation enables a homogeneous diffusion of thymol within the hive, contributing to colony safety when used according to label directions.

 

Availability

 

Thymoflex® has received EPA federal approval and will be made available to beekeepers in the United States in accordance with individual state registrations.

 

More information about Thymoflex® will be available soon on the Véto-pharma website: https://www.veto-pharma.com

 

A long-standing commitment to honey bee health

Honeybee health is affected by multiple factors, including climate change, habitat loss, nutritional stress, pesticide exposure, and pathogens, among which varroa plays a central role. Addressing these challenges requires robust, flexible, and science-based solutions.

 

For more than 25 years, Véto-pharma has focused exclusively on honey bee health, developing and manufacturing products designed to support beekeepers worldwide in protecting their colonies and securing the future of pollination.

 

Sean Smith, CEO of Eden Research, commented:

 

"We are delighted to be able to play such a key role in the delivery of vital care products to keep bee populations thriving. Our partnership with Véto-pharma is representative of our commitment to diversifying our business model and revenue streams by applying our sustainable chemical technology to other sectors beyond arable agriculture."

 

-- ENDS --

 

For further information, contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

 

 

01285 359 555

Cavendish Capital Markets Limited (Nominated advisor and joint broker)

Giles Balleny / Elysia Bough (Corporate Finance)

Harriet Ward (Corporate Broking)Dale Bellis (Sales)

 

 

020 7220 0500

Oberon Capital (Joint Broker)

020 3179 5300

Nick Lovering

Mike Seabrook

Adam Pollock

 

Hawthorn Advisors (Financial PR)

Jamie Plotnek

 

eden@hawthornadvisors.com

 

 

Notes to Editors:

 

About Eden Research

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

For more information about Eden, visit: www.edenresearch.com.

 

Follow Eden on LinkedInTwitter and YouTube

About Véto-pharma

Founded in 1982, Véto-pharma is a veterinary pharmaceutical laboratory dedicated to honey bee health. The company is recognised globally for its expertise, innovation, and high-quality products developed and manufactured in France.

For more information about Véto-pharma, visit: https://www.veto-pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAIBMRTMTMMBAF
Date   Source Headline
27th May 20267:00 amRNSDirectorate change
28th Apr 20267:00 amRNSTrading Update
16th Apr 20262:59 pmRNSHolding(s) in Company
14th Apr 20264:30 pmRNSHolding(s) in Company
14th Apr 20263:31 pmRNSHolding(s) in Company
13th Apr 202611:31 amRNSHolding(s) in Company
10th Apr 20267:00 amRNSCompletion of Conditional Placing and TVR
8th Apr 202612:10 pmRNSSatisfaction of Conditions of Conditional Placing
2nd Apr 20267:00 amRNSThymolflex EPA approval
19th Feb 20263:59 pmRNSHolding(s) in Company
19th Feb 20261:29 pmRNSHolding(s) in Company
18th Feb 20269:40 amRNSResult of General Meeting and Total Voting Rights
5th Feb 20262:50 pmRNSResult of Retail Offer
2nd Feb 20261:01 pmRNSLaunch of Retail Offer
2nd Feb 202612:57 pmRNSProposed Placing and Subscription
9th Jan 20267:00 amRNSNovellus+ Regulatory Authorisation in Chile
7th Jan 20267:00 amRNSMevalone Label Extension in France
18th Dec 20257:00 amRNSAppointment of Syngenta as Distribution Partner
20th Nov 20257:00 amRNS3LOGY Label Extension in Italy
17th Nov 20257:00 amRNSEcovelex 2025 Approval in Italy
17th Sep 20259:45 amRNSDirector/PDMR Shareholdings
17th Sep 20258:36 amRNSDirector/PDMR Shareholdings
17th Sep 20257:00 amRNSHalf Yearly Report
15th Sep 20257:00 amRNSNotice of Results
18th Jun 20251:40 pmRNSResult of AGM
18th Jun 20257:00 amRNSAGM Statement
16th Jun 20257:00 amRNSEcovelex Partnership with Royal Holloway
27th May 20255:22 pmRNSNotice of AGM
13th May 20257:00 amRNSMevalone Approval in California - Powdery Mildew
9th May 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
6th May 202512:08 pmRNSHolding(s) in Company
6th May 20257:00 amRNSPreliminary results for the year ended 31 Dec 2024
10th Apr 20257:00 amRNSThymol Supply Agreement For Bee Health
1st Apr 202510:08 amRNSDirector/PDMR Shareholdings
24th Mar 20257:00 amRNSAppointment of Distribution Partner in Kenya
10th Mar 20257:00 amRNSAppointment of Joint Broker
5th Mar 202512:52 pmRNSDirector/PDMR Shareholding
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
4th Mar 20252:13 pmRNSDirector/PDMR Shareholdings
6th Feb 20252:08 pmRNSDirector/PDMR Shareholding
5th Feb 20257:00 amRNS-RInvestor Presentation via Investor Meet Company
28th Jan 202510:36 amRNSDirector/PDMR Shareholdings
13th Jan 20257:12 amRNSTrading Update
20th Dec 20247:00 amRNSRegulatory approval for Novellus+ in Mexico
16th Dec 20247:00 amRNSAppointment of Distributor in Austria
11th Dec 20247:00 amRNSMevalone Organic Input Registration in Germany
7th Nov 20247:01 amRNSTrading Update
7th Nov 20247:00 amRNSEcovelex Approval in Italy
8th Oct 202411:24 amRNSOTCQB exchange update
23rd Sep 20247:00 amRNSHalf yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.